1 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 3 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Peripheral T-cell Lymphomas (PTCL): new trials by email Literature Review of Peripheral T-cell Lymphomas (PTCL) trials Research Report on Peripheral T-cell Lymphomas (PTCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib Combined With GemOx in RR PTCL golidocitinib, GEMOX - Peripheral T-cell Lymphomas (PTCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 31 | 2025-12-20 | 2025-12-12 |
| Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine (Dose level 21), Lenalidomide and Gemcitabine (Dose level 31) - Peripheral T-cell Lymphomas (PTCL) | Phase 1 / Phase 2 | Terminated | National Health Research Institutes, Taiwan | 12 | 2022-06-15 | 2024-07-08 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies CT125A cells, Cyclophosphamide, fludarabine - CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Unknown | Huazhong University of Science and Technology | 18 | 2021-03-01 | 2021-02-23 |
| Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas Ro-CHOEP-21 (PHASE I), Ro-CHOEP-21 (PHASE II) - Peripheral T-cell Lymphomas (PTCL), PTCL-NOS | Phase 1 / Phase 2 | Completed | Fondazione Italiana Linfomi - ETS | 89 | 2014-09-01 | 2026-08-19 |
Lymphoma, T-Cell, Peripheral (4) · Hematologic Neoplasms (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, T-Cell (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
CF regimen (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Gemcitabine (1) · Lenalidomide (1) · Prednisone (1) · Vincristine (1) · romidepsin (1)
Fondazione Italiana Linfomi - ETS (1) · Huazhong University of Science and Technology (1) · National Health Research Institutes, Taiwan (1) · Ruijin Hospital (1)
Italy (1) · Taiwan (1)
Jianfeng Zhou, PhD, MD (1) · Paolo Corradini, Prof (1) · Tsang-Wu Liu (1)